Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:41 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 9,976 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TARGET Clear all
Completed Early Phase 1 Interventional

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

NCT05704933
View directory record Official record
Conditions
Metastatic Melanoma, Metastasis to Brain
Interventions
Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Standard of Care Craniotomy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 1, 2026, 10:41 PM EST
Completed Phase 4 Interventional

Young Hearts, Strong Starts

NCT01893593
View directory record Official record
Conditions
Cardiovascular Risk Reduction
Interventions
Intervention, Control
Other
Lead sponsor
RTI International
Other
Eligibility
3 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Nov 1, 2026, 10:41 PM EST
Active, not recruiting Phase 2 Interventional

Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

NCT03121014
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Fludarabine, Busulfan, ATG, Total Marrow Irradiation, Stem Cell Product Infusion, Tacrolimus, Methotrexate
Drug · Radiation · Procedure
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 1, 2026, 10:41 PM EST
Completed Not applicable Interventional Results available

NIRTRAKS Post-Market Study (NIRTRAKS)

NCT02455804
View directory record Official record
Conditions
de Novo Stenotic Lesions in Native Coronary Arteries
Interventions
Stenting procedure
Device
Lead sponsor
Medinol Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Nov 1, 2026, 10:41 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)

NCT00833898
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer
Interventions
Paced respiration as part of PEPRR, PEPRR
Device · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Nov 1, 2026, 10:41 PM EST
Not listed No phase listed Observational

Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index

NCT00939263
View directory record Official record
Conditions
Deglutition Disorders, Esophageal Diseases, Eosinophilia
Interventions
assessment of disease activity using the EEsAI
Other
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
Not listed
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Scottsdale, Arizona • San Diego, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Nov 1, 2026, 10:41 PM EST
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Nov 1, 2026, 10:41 PM EST
Completed No phase listed Interventional Accepts healthy volunteers Results available

Oxygen Reserve Index (ORi) Expanded Data Set Validation of INVSENSOR00025

NCT04079816
View directory record Official record
Conditions
Healthy
Interventions
INVSENSOR00025
Device
Lead sponsor
Masimo Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Nov 1, 2026, 10:41 PM EST
Completed Phase 1 Interventional Results available

A Phase 1 Study in Patients With Solid Tumors

NCT01215916
View directory record Official record
Conditions
Solid Tumors
Interventions
LY573636, Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Nov 1, 2026, 10:41 PM EST
Not yet recruiting Phase 1Phase 2 Interventional

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07552558
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Interventions
Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
Radiation · Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 1, 2026, 10:41 PM EST
Completed Not applicable Interventional Results available

First CRUSH: Piloting the Preliminary Feasibility and Acceptability of the Competence in Romance and Understanding Sexual Health (CRUSH) Curriculum

NCT05910658
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Competence in Romance and Understanding Sexual Health (CRUSH)
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 1, 2026, 10:41 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of ORG 34517 for Major Depression With Psychotic Features

NCT00226278
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
ORG 34517
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Nov 1, 2026, 10:41 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Transforming Curiosity Into Donation

NCT07793890
View directory record Official record
Conditions
Kidney Transplant, Kidney Donor, Drop Out, High Risk, Living Kidney Donation, Living Donor of Kidney
Interventions
Living Kidney Donor Support
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 1, 2026, 10:41 PM EST
Recruiting Phase 3 Interventional

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

NCT05317858
View directory record Official record
Conditions
Brain Tumor, Non Small Cell Lung Cancer
Interventions
Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab, Cemiplimab, Nivolumab, Iptilimumab
Device · Drug
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 100 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
12
States / cities
Phoenix, Arizona • Newport Beach, California • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 1, 2026, 10:41 PM EST
Active, not recruiting Not applicable Interventional

Enhancing Care & Outcomes for Patients During the First Postpartum Year

NCT06615076
View directory record Official record
Conditions
Postpartum Period, Pregnancy, Hypertension, Pregnancy Induced
Interventions
Postpartum Visits
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 1, 2026, 10:41 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimizing an mHealth Intervention to Change Food Purchasing Behaviors for Cancer Prevention

NCT04947150
View directory record Official record
Conditions
Cancer
Interventions
Location-triggered notification, Reflections on benefits of change, Coach monitoring, Household support
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Nov 1, 2026, 10:41 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of High Functional Resistance Training Program on Arterial Stiffness

NCT06935318
View directory record Official record
Conditions
Training Study
Interventions
Exercise, Control
Other
Lead sponsor
Salisbury University
Other
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Nov 1, 2026, 10:41 PM EST
Active, not recruiting Phase 2 Interventional

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

NCT05622318
View directory record Official record
Conditions
Graft-versus-host Disease
Interventions
Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Ruxolitinib
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
60 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 1, 2026, 10:41 PM EST
Completed Not applicable Interventional Results available

Feasibility Electrical Stimulation Study for Visual Hallucinations

NCT04870710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
transcranial electrical stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Nov 1, 2026, 10:41 PM EST
Completed Not applicable Interventional

Affective Management Training for Cannabis Misuse

NCT03432013
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
CUD-AMT, SUD-CBT
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 25 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Nov 1, 2026, 10:41 PM EST
Completed Not applicable Interventional Results available

Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons

NCT02059408
View directory record Official record
Conditions
Hypertension
Interventions
Screen-Educate, Screen-Educate and Intensify Treatment
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
1,819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Nov 1, 2026, 10:41 PM EST
Terminated Phase 2 Interventional Results available

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

NCT02954991
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Glesatinib, Sitravatinib, Mocetinostat, Nivolumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
25
States / cities
Yuma, Arizona • Beverly Hills, California • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Nov 1, 2026, 10:41 PM EST
Not listed No phase listed Observational

Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

NCT06516458
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis, Relapsing-Remitting
Interventions
Camera Based Kinematic Analysis
Diagnostic Test
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Nov 1, 2026, 10:41 PM EST
Not listed Not applicable Interventional

Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis

NCT06074315
View directory record Official record
Conditions
Distal Lateral Subungual Onychomycosis, Onychomycosis
Interventions
Nail Genesis DLSO Product, Nail Genesis DLSO Product (vehicle only)
Device
Lead sponsor
Nail Genesis LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Fayetteville, Arkansas • Montclair, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Nov 1, 2026, 10:41 PM EST